Cardiovascular Toxicity in Patients Treated for Childhood Cancer
Published: March 19, 2025
- Pediatric cardio-oncology is a multidisciplinary field focused on cardiac complications during and after cancer treatment. Although children represent about 5% of new cancer diagnoses annually, their five-year survival rate exceeds 85%, resulting in nearly 500,000 survivors.
- Despite advancements, short- and long-term side effects of chemotherapy continue to pose risks for cardiovascular disease (CVD), including ventricular dysfunction, coronary artery disease, and arrhythmias, presenting a significant challenge for young patients.
- This scientific statement reviews current data on pediatric patients and survivors of pediatric cancer, offering updates on established cardiotoxic therapies, care transitions after treatment, the impact of cardiovascular (CV) risk factors, and approaches to exercise and cardiac rehabilitation.
Supporting Materials
Recommended Reading
- Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy
- Cardio-Oncology Drug Interactions
- Treatment Strategies for Cardiomyopathy in Children
- Environmental Exposures and Pediatric Cardiology
- 2024 Guideline for the Management of Hypertrophic Cardiomyopathy